Navigation Links
Study Confirms that OrbusNeich's Genous™ Stent Effectively Captures Circulating Endothelial Progenitor Cells to Accelerate Re-Endothelialization and Decrease Thrombogenicity
Date:7/11/2011

promoting EPC capture and reducing acute thrombogenicity," said Renu Virmani, M.D., of the CVPath Institute Inc. in Gaithersburg, Md., and co-author of publication. "The Genous Stent appears to not only promote the adhesion of human EPCs, but it also reduces the adhesion of fibrin, platelets and inflammatory cells, all of which are important for the prevention of thrombus."

Further studies validating the EPC capture concept were conducted in vitro and in two animal models. An in vitro cell-capture assay demonstrated a preferential adhesion of human peripheral blood-derived CD34+ cells to the Genous Stent, with 86 percent of the attached cells positive for CD34 compared to 26 percent of cells on the BMS. In a baboon AV shunt model, the investigators showed that the Genous Stent inhibits in-stent thrombosis, as indicated by a significant increase in platelet deposition on the BMS compared to the Genous Stent. In a rabbit endothelial denudation model, qPCR analysis of endothelial marker expression indicated that the Genous Stent significantly promotes re-endothelialization at seven days compared to BMS.

About Genous  

Genous is OrbusNeich's patented EPC capture technology that promotes the accelerated natural healing of the vessel wall after the implantation of blood-contact devices such as stents. The technology consists of an antibody surface coating that attracts EPCs circulating in the blood to the device to form an endothelial layer that provides protection against thrombosis and modulates restenosis.

The Genous Stent, which has been commercially available in more than 60 countries since 2005, has been proven as a safe, effective alternative to drug eluting stents and is supported by data from more than 6,000 patients in company-sponsored clinical studies. There is a growing body of evidence from multiple clinical studies that the Genous Stent is effective for patients who are non-responsive to or cannot toler
'/>"/>

SOURCE OrbusNeich
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
5. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
6. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
7. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
8. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
9. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
10. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
11. Sarasotas Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... Sept. 17, 2014  Millions of people suffer from neck ... Recently the FDA approved the launch of ... innovative implant device developed by Spinal Kinetics, which may offer ... and or arm pain. Hospital for Special Surgery (HSS), the ... hospital in New York City and ...
(Date:9/17/2014)... According to a new market research report ... Display, & Microprocessor/MCU), by Application (Imaging, Medical Therapeutics, Diagnosis, ... Global Forecast to 2020", published by MarketsandMarkets, the total ... $56.50 Billion by 2020, growing at a CAGR of ... market data Tables and 71 Figures spread through 312 ...
(Date:9/17/2014)... N.J. , Sept. 17, 2014  The ... (MDM&C), today announced that it will serve as ... Benefits and Avoiding the Risks of Healthcare Reform," ... that will examine delivery systems, reimbursement, compliance and ... Care Act. Logo -  http://photos.prnewswire.com/prnh/20140916/146606 ...
Breaking Medicine Technology:Cervical Disc Clinical Trial for People with Neck and Arm Pain Set to Begin at Hospital for Special Surgery 2Medical Electronics Market Worth $56.50 Billion by 2020 2Medical Electronics Market Worth $56.50 Billion by 2020 3Medical Electronics Market Worth $56.50 Billion by 2020 4Three Leading Healthcare Organizations Sponsor Conference to Examine Opportunities and Risks of Healthcare Reform for Providers 2
... Pa., Jan. 12, 2011 ECRI Institute® ( ... the best approaches to improving patient care, is ... Health Devices Achievement Award program. The award ... technology management. (Logo: http://photos.prnewswire.com/prnh/20110112/DC29081LOGO ...
... 2011, what will be the major trends in the ... regulations affect what,s next and what,s new?  What will ... competitive corporate landscape?  When it comes to market research, ... the job done right? The answers to these questions ...
Cached Medicine Technology:ECRI Institute's 2011 Health Devices Achievement Award - Call for Entries 2ECRI Institute's 2011 Health Devices Achievement Award - Call for Entries 3Pharma Industry Leaders to Reveal Hottest, Latest Trends for Pharma & Biotech at Groundbreaking Event 2
(Date:9/17/2014)... Present-day Europeans are the descendants of at least ... new study. Previous research suggested that ... farmers. But, a new genetic analysis involving ancient ... of Ancient North Eurasians. Nearly all present-day Europeans ... researchers from Harvard Medical School said. , , ...
(Date:9/17/2014)... HealthDay Reporter WEDNESDAY, Sept. 17, 2014 (HealthDay ... why antibiotic-resistant bacteria can thrive in a hospital setting. ... the culprit. They can easily enter bacteria and move from ... makes bacteria drug-resistant, a new study finds. "The plasmids ... class of antibiotic called carbapenems," said the study,s co-author, Dr. ...
(Date:9/17/2014)... might be able to reduce the need for invasive ... autoimmune disease lupus. , In a new study, researchers ... from nephritis kidney inflammation to interstitial fibrosis, ... A kidney biopsy is the only existing way to ... extent. , The model could also be used to ...
(Date:9/17/2014)... 17, 2014 Today, Blue Shield ... in third-quarter grantmaking. This body of grants aims to ... innovations in care delivery, as well as to develop ... Grants will also strengthen the capacity of both domestic ... and create new entry points for domestic violence screening ...
(Date:9/17/2014)... 17, 2014 In a country where ... on a regular basis, how can Americans find healthy ... Hyland’s Stress Challenge , a 5-day interactive journey ... stress-free life. From September 29th – October 3rd, ... content relating to specific topics that promote natural solutions ...
Breaking Medicine News(10 mins):Health News:Europeans Are Descendants of at Least 3 Ancient Human Groups: Study 2Health News:Europeans Are Descendants of at Least 3 Ancient Human Groups: Study 3Health News:Researchers Discover How Bacteria Resist Antibiotics in Hospitals 2Health News:Researchers Discover How Bacteria Resist Antibiotics in Hospitals 3Health News:Math model designed to replace invasive kidney biopsy for lupus patients 2Health News:Blue Shield of California Foundation Awards $5 Million in Third-Quarter Grants 2Health News:Stress Less with the Hyland's 5-Day Stress Challenge 2
... to this new research on mountain biking it is observed ... from University Hospital in Innsbruck, Austria,// presented his findings of ... extreme mountain bikers and 30 non-bikers took part in the ... more than two hours a day, six days a week, ...
... effective utility tool to the field of medicine. An ... about their treatment. The days when doctors told you ... expect to participate in the decision-making process. But sometimes ... messages and new research comes up all the time. ...
... are more likely to suffer from behavioural problems, a ... growth hormone not only boosted growth in children,// but ... ,Lead researcher Dr Derick Beens, professor of ... said: "We believe this work demonstrates that all very ...
... has always been an ongoing argument regarding the do's and ... suggest a new and better way through the dieting controversy.// ... fashion being the 'low carb' approach - for many decades ... at the 'no diet' women's retreat Green Mountain in the ...
... events in detail, older people recall more about thoughts, ... age - some researchers believe that it deteriorates,// others ... Psychologists in Toronto have been comparing how people of ... ,They studied a group of 15 younger ...
... is better than conventional treatment for managing asthma ... of immune cells known eosinophils increase// in the ... at how targeting this build up of eosinophils ... an asthma attack. ,The conventional treatment ...
Cached Medicine News:
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: